A Study to Investigate Efficacy and Safety of OG-6219 BID in 3 Dose Levels Compared with Placebo in Participants Aged 18 to 49 with Moderate to Severe Endometriosis-related Pain (ELENA)

Organon

Status and phase: Active, not recruiting; Phase 2

Conditions: Endometriosis

Treatments: Drug: Placebo; Drug: OG-6219

Study type: Interventional

Funder types: Industry

Identifiers

NCT05560646

OG-6219-P001

Details and patient eligibility

About

The purpose of this global Phase 2 study is to determine the efficacy, safety, and tolerability of 3 dose levels of OG-6219 in pre-menopausal women between 18 and 49 years of age (inclusive), who have moderate to severe endometriosis-related pain.

Full description

This is a global multicenter, Phase 2a/b, randomized, double-blind, Placebo-controlled study to assess the efficacy, safety, and tolerability of 3 dose levels of OG-6219, in pre-menopausal women 18 to 49 years of age (inclusive), who have been surgically diagnosed with endometriosis with moderate to severe endometriosis-related pain. This study includes treatment lasting approximately 16 weeks in total and is followed by a Safety Follow-up visit.

Pre-menopausal females aged 18 to 49 years old (inclusive), who have been surgically diagnosed with endometriosis will be screened and randomly assigned to study treatment. A minimum subset of 10 participants per treatment group (including Placebo group) will be voluntarily enrolled for optional intensive PK sampling for the entire duration of the study.

Enrollment: 380 estimated patients

Sex: Female

Ages: 18 to 49 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Pre-menopausal females of age 18 to 49 years old (inclusive) at the time of signing Informed Consent (V1).
• Surgically (laparoscopy or laparotomy) diagnosed with endometriosis
• Moderate to severe endometriosis-related pelvic pain
• Regular menstrual cycles
• Is not expected to undergo a planned gynecological surgery or other surgical procedures for treatment of endometriosis during study participation.
• Normal breast exam at V1. In participants of ≥40 years mammography or contrast-enhanced breast MRI performed within the last 12 months prior to Screening (V1) without clinically significant abnormal findings.
• Agree not to participate in another interventional study while participating in the present study.
• Able and willing to adhere to study procedures, including
• agree to use 2 forms of non-hormonal contraception throughout the study
• Must be willing and able to provide signed informed consent before any study-related activities
• Has demonstrated compliance with ≥75% of eDiary entries
• Has a negative pregnancy test

Exclusion criteria

• Surgical history of hysterectomy and/or bilateral oophorectomy
• Chronic pelvic and/or non-pelvic pain not caused by endometriosis that requires chronic analgesic or other chronic therapy
• Undiagnosed (unexplained), abnormal vaginal bleeding not associated with endometriosis within the past 6 months before screening.
• Presence of high-risk human papillomavirus (HPV).
• Has an active sexually transmitted infection (STI) (eg, gonorrhea, chlamydia, or trichomonas).
• Intends to become pregnant or breast feed during study participation or has a known or suspected pregnancy.
• History of malignancy (except for basal cell or squamous cell skin cancer) before signing informed consent.
• History of family history of hereditary abnormal hemoglobin or an enzyme deficiency that can result in methemoglobinemia.
• Has a medical condition associated with hemolytic anemia
• Known human immunodeficiency virus infection, and/or acute or active, recurrent/relapsing, or chronic infection (eg, hepatitis A, B, or C virus)
• Has a clinically significant abnormal ECG or QT interval prolongation
• Used any medication that is either a sensitive substrate, moderate, or strong inhibitor or inducer of CYP3A4 within 30 days or 10 half-lives (whichever is longer) prior to the planned first day of dosing.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

380 participants in 4 patient groups, including a placebo group

Group A: OG-6219 Dose 1

Experimental group

Description:

Group A: OG-6219 Dose 1 BID

Treatment:

Drug: OG-6219

Group B: OG-6219 Dose 2

Experimental group

Description:

Group B: OG-6219 Dose 2 BID

Treatment:

Drug: OG-6219

Group C: OG-6219 Dose 3

Experimental group

Description:

Group C: OG-6219 Dose 3 BID

Treatment:

Drug: OG-6219

Group D: Placebo

Placebo Comparator group

Description:

Group D: Placebo BID

Treatment:

Drug: Placebo